Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Breast Cancer Res Treat. 2021 Feb 16;187(1):135–144. doi: 10.1007/s10549-021-06100-2

Table 3.

Summary of clinical outcomes in ER+/HER2− patients younger than age 45 stratified by amount of change in NTx levels from baseline to 12 months. Data are presented as number of events / number of patients in each group followed by hazard ratio and 95% confidence interval

Recurrence Bone Recurrence Non-Bone Recurrence Breast Cancer Survival Overall Survival
Age < 45, ER+/HER2− ΔNTx Low: 3/7
ΔNTx High: 3/7
HR 1.99
[0.30–13.4]		 ΔNTx Low: 1/7
ΔNTx High: 1/7
HR 1.48
[0.06–39.4]		 ΔNTx Low: 2/7
ΔNTx High: 2/7
HR 6.55
[0.55–78.7]		 ΔNTx Low: 3/7
ΔNTx High: 3/7
HR 1.99
[0.30–13.4]		 ΔNTx Low: 4/7
ΔNTx High: 4/7
HR 2.44
[0.44–13.6]